Regulation of Mucosal Healing in Inflammatory Bowel Disease
Launched by TERRENCE A BARRETT · Aug 4, 2020
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different types of colon ulcers heal in patients with inflammatory bowel diseases (IBD), like ulcerative colitis and Crohn's disease, compared to healthy individuals and those with rheumatoid or psoriatic arthritis. Researchers want to understand the gene activity and energy function in cells during the healing process. Participants will undergo a procedure where small samples of tissue are taken from their colons, both at the start of the study and again later, to compare how healing happens in different groups.
To be eligible for this trial, you must be diagnosed with ulcerative colitis or Crohn's disease and either have not responded to certain treatments (like biologic therapies) or have never received them before. Alternatively, you could qualify if you have rheumatoid or psoriatic arthritis and are currently receiving a specific type of treatment called anti-TNF therapy. There is also a group for individuals without IBD, who have normal colon tissue. Participants can expect to have biopsies, which are small tissue samples, taken during the study. It's important to note that certain health conditions or treatments may prevent someone from joining the trial, so discussing your situation with a doctor would be necessary.
Gender
ALL
Eligibility criteria
- Inclusion Criteria (Group 1):
- • Diagnosed ulcerative colitis or Crohn's disease
- • Biologic failure or naive to biologic treatment
- • Eligible to be treated with anti-TNF therapy
- Inclusion Criteria (Group 2):
- • Diagnosed rheumatoid or psoriatic arthritis
- • Receiving anti-TNF antibody therapy at the time of enrollment
- Inclusion Criteria (Group 3):
- • Endoscopically unremarkable colonic mucosa
- • Absence of inflammatory bowel disease
- Exclusion Criteria:
- • Classified in an anesthesia risk group, ASA Class =4
- • History of bleeding diathesis or coagulopathy
- • Stroke or transient neurological attack with the last 6 months
- • Pregnant
- • Receiving anticoagulants or anti-platelet medications other than low-dose aspirin
- • Receiving steroid therapy or metformin
- • HIV positive
- • Incarceration
- • History of total proctocolectomy
- • History of system chemotherapy within 18 months
- • Uncontrolled intercurrent illness
About Terrence A Barrett
Terrence A. Barrett is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative studies. With a strong commitment to ethical practices and scientific rigor, Mr. Barrett leads initiatives that explore novel therapeutic approaches across various medical fields. His expertise in clinical trial design and execution ensures that trials are conducted efficiently and effectively, adhering to the highest standards of regulatory compliance and participant safety. By fostering collaboration among healthcare professionals and researchers, Terrence A. Barrett plays a pivotal role in translating scientific discoveries into meaningful clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lexington, Kentucky, United States
Patients applied
Trial Officials
Terrence Barrett, MD
Principal Investigator
University of Kentucky
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials